Merck & Co., headquartered in Rahway, New Jersey, employs 72,000 people and provides health solutions through pharmaceuticals, vaccines, and animal health products. Its lead candidate is MK-6070, targeting DLL3.
MRK has been in the news recently: Merck & Co. Inc. announced positive Phase 3 results for enlicitide decanoate, demonstrating its safety and efficacy in treating hypercholesterolemia in patients on statins. The company shows strong growth potential, with a target stock price of $90 supported by its fundamentals and late-stage pipeline developments.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
